Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136437 | 0.85 | MAPT (0.42) | MAPTSMPD1RENL3MBTL1TSHR | |
| SCHEMBL4598605 | 0.84 | TSHR (0.33) | MAPTRENTSHRCYP3A4TP53 | |
| SCHEMBL4598609 | 0.84 | TSHR (0.33) | MAPTRENTSHRCYP3A4TP53 | |
| SCHEMBL1040699 | 0.84 | MAPT (0.39) | MAPTSMPD1RENL3MBTL1TSHR | |
| SCHEMBL1034992 | 0.84 | MAPT (0.39) | MAPTSMPD1RENL3MBTL1TSHR | |
| SCHEMBL3908343 | 0.81 | MAPT (0.42) | MAPTSMPD1RENL3MBTL1TSHR | |
| SCHEMBL1036573 | 0.79 | MAPT (0.41) | MAPTSMPD1RENL3MBTL1TSHR | |
| SCHEMBL4647385 | 0.78 | MAPT (0.41) | MAPTSMPD1RENL3MBTL1TSHR | |
| SCHEMBL1034990 | 0.78 | MAPT (0.40) | MAPTSMPD1RENL3MBTL1TSHR | |
| SCHEMBL3906082 | 0.78 | MAPT (0.42) | MAPTSMPD1RENL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | MAPT 4794/4885SMPD1 1275/4885REN 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.